Abstract: The present invention refers to a novel replication deficient influenza A vims which is inducing high levels of type I interferon (IFN) in cells infected by said vims, comprising an NS1 protein with a functional effector domain and a non-functional RNA binding domain with a deletion of at least 15 amino acids within the N-terminal 80 amino acids of the NS1 protein and its use for antiviral treatment.

Abstract: The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.

Abstract: The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.

Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising said modified influenza virus is provided and its use for prevention of influenza infection.

Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.

Abstract: The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising said modified influenza virus is provided and its use for prevention of influenza infection.

Abstract: The invention relates to a simple and efficient process for isolating viruses from various sources and for producing live attenuated influenza vaccines in a serum-free Vero cell culture under conditions where alterations in the surface antigens of the virus due to adpative selection are minimized or prevented. The process does not require purification of the virus-containing supernatant harvested from the cell culture nor post-incubation treatment of the viruses for HA activation. The invention further relates to influenza A and B master strain candidates and to vaccines made thereof.

Abstract: A motor vehicle 1, 101 is disclosed having front and rear roof members 5 and 6 which can be moved from raised to stowed positions to change the style of the motor vehicle from a two box style to a convertible or pick-up style. The rear roof member 6 is stowed at an inclined angle between two rows of seats 9, 10 of the motor vehicle 1, 101 so as to occupy little space within the vehicle 1, 101.

Abstract: A stowage mechanism 30 for a rear roof member 6 of a motor vehicle 1, 101 is also disclosed which is particularly small allowing it to be easily packaged in the motor vehicle 1, 101. The stowage mechanism 30 uses a combination of a chain 31 and a guide slot 32 to control the movement of the rear roof member 6 between raised and stowed positions which require the rear roof member 6 to be rotated, moved forwards and then lowered to reach the stowed position.

Abstract: A motor vehicle 1, 101 is disclosed having front and rear roof members 5 and 6 which can be moved from raised to stowed positions to change the style of the motor vehicle from a two box style to a convertible or pick-up style. The rear roof member 6 is stowed at an inclined angle between two rows of seats 9, 10 of the motor vehicle 1, 101 so as to occupy little space within the vehicle 1, 101.

Abstract: A stowage mechanism 30 for a rear roof member 6 of a motor vehicle 1, 101 is also disclosed which is particularly small allowing it to be easily packaged in the motor vehicle 1, 101. The stowage mechanism 30 uses a combination of a chain 31 and a guide slot 32 to control the movement of the rear roof member 6 between raised and stowed positions which require the rear roof member 6 to be rotated, moved forwards and then lowered to reach the stowed position.

Abstract: The invention relates to a recombinant NS gene of an influenza A virus comprising a functional RNA binding domain and a gene sequence modification after nucleotide position 400 of the NS1 gene segment, counted on the basis of influenza A/PR/8/34 Virus, wherein the modification bars transcription of the remaining portion of the NS1 gene segment. It further relates to embodiments, wherein the modification comprises deletions, insertions, or a shift of the open reading frame, and particularly to constructs comprising an insertion of an autocleavage site 2A, the nef gene from HIV-1 or the sequence encoding the ELDKWA-epitope of gp4l of HIV-1. The invention also relates to influenza virus transfectants that contain the modified NS gene and have an IFN inducing phenotype but which may or may not be sensitive towards IFN. The invention also relates to vaccines comprising such a chimeric virus.

Abstract: The invention relates to a simple and efficient process for isolating viruses from various sources and for producing live attenuated influenza vaccines in a serum-free Vero cell culture under conditions where alterations in the surface antigens of the virus due to adpative selection are minimized or prevented. The process does not require purification of the virus-containing supernatant harvested from the cell culture nor post-incubation treatment of the viruses for HA activation. The invention further relates to influenza A and B master strain candidates and to vaccines made thereof.

Abstract: The invention relates to a recombinant NS gene of an influenza A virus comprising a functional RNA binding domain and a gene sequence modification after nucleotide position 400 of the NS1 gene segment, counted on the basis of influenza A/PR/8/34 Virus, wherein the modification bars transcription of the remaining portion of the NS1 gene segment. It further relates to embodiments, wherein the modification comprises deletions, insertions, or a shift of the open reading frame, and particularly to constructs comprising an insertion of an autocleavage site 2A, the nef gene from HIV-1 or the sequence encoding the ELDKWA-epitope of gp4l of HIV-1. The invention also relates to influenza virus transfectants that contain the modified NS gene and have an IFN inducing phenotype but which may or may not be sensitive towards IFN. The invention also relates to vaccines comprising such a chimeric virus.